Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma

NCT02101905 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02101905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2016
Completion date
October 30, 2024
Enrollment
29 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, gliosarcoma, mixed glioma, recurrent adult brain neoplasm, recurrent glioblastoma